Psychemedics Corporation PMD
- Market cap
- $15.7M
- P/E
- 0.0×
Follow PMD
Target Price Range
Analyst price targets
Free account| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | 7.76 | 13.81 | 13.94 | 7.12 | 3.58 | 4.95 | 4.85 | 2.06 | 1.11 |
Analyst estimates 2025–2027 Powerpack |
Low Price
|
||
| — | 26.00 | 27.99 | 22.88 | 19.64 | 10.69 | 8.90 | 7.77 | 6.75 | 3.93 |
High Price
|
|||
| — | 206 | 231 | 250 | 204 | 138 | 139 | 133 | 116 | 101 |
Employees
|
|||
| — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | 39 | 40 | 43 | 38 | 21 | 25 | 25 | 22 | 20 |
Revenue
|
|||
| — | 55.03% | 49.93% | 48.32% | 43.64% | 22.87% | 41.21% | 36.81% | 38.07% | 36.07% |
Gross Margin
|
|||
| — | 10 | 8 | 8 | 3 | (6) | (1) | (1) | (3) | (2) |
EBT
|
|||
| — | 25.59% | 20.60% | 17.93% | 8.11% | (29.05%) | (3.30%) | (4.12%) | (15.56%) | (9.73%) |
EBT Margin
|
|||
| — | 7 | 6 | 5 | 2 | (4) | (1) | (1) | (4) | (2) |
Net Income
|
|||
| — | 2 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 2 |
Depreciation
|
|||
| — | 7.16 | 7.24 | 7.76 | 6.83 | 3.87 | 4.49 | 4.49 | 3.85 | 3.36 |
Revenue/Sh
|
|||
| — | 1.22 | 1.10 | 0.83 | 0.28 | (0.70) | (0.12) | (0.19) | (0.72) | (0.32) |
Earnings/Sh
|
|||
| — | 1.70 | 1.67 | 1.44 | 0.78 | (0.74) | 0.07 | 0.87 | (0.26) | 0.16 |
Cash Flow/Sh
|
|||
| — | (0.37) | (0.22) | (0.22) | (0.30) | (0.15) | (0.03) | (0.03) | (0.03) | (0.01) |
Capex/Sh
|
|||
| — | 1.33 | 1.45 | 1.22 | 0.48 | (0.89) | 0.04 | 0.84 | (0.29) | 0.14 |
Free CF/Sh
|
|||
| — | 2.87 | 3.40 | 3.41 | 3.05 | 2.27 | 2.21 | 1.91 | 1.16 | 0.87 |
Book Value/Sh
|
|||
| — | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Shares
|
|||
| — | 19.58 | 18.68 | 19.12 | 32.68 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | 3.35 | 2.86 | 2.05 | 1.34 | 1.32 | 1.56 | 1.10 | 0.88 | 0.67 |
PS Ratio
|
|||
| — | 8.38 | 6.10 | 4.66 | 3.00 | 2.25 | 3.18 | 2.58 | 2.92 | 2.56 |
PB Ratio
|
|||
| — | 3.34 | 2.74 | 1.90 | 1.22 | 1.38 | 1.53 | 0.93 | 0.81 | 0.61 |
EV/Sales
|
|||
| — | 18.52 | 14.74 | 13.12 | 19.99 | (5.71) | 386.11 | 5.14 | (10.45) | 14.92 |
EV/FCF
|
|||
| — | 9 | 9 | 8 | 4 | (4) | 0 | 5 | (1) | 1 |
Op' Cash Flow
|
|||
| — | (2) | (1) | (1) | (2) | (1) | 0 | 0 | 0 | 0 |
Capex
|
|||
| — | 7 | 8 | 7 | 3 | (5) | 0 | 5 | (2) | 1 |
FCF
|
|||
| — | 6 | 10 | 10 | 7 | 6 | 4 | 4 | 2 | 2 |
Working Cap'
|
|||
| — | 3 | 3 | 2 | 3 | 4 | 1 | 1 | 0 | 0 |
Total Debt
|
|||
| — | (1) | (5) | (6) | (5) | 1 | (1) | (4) | (2) | (1) |
Net Debt
|
|||
| — | 16 | 19 | 19 | 17 | 13 | 12 | 11 | 7 | 5 |
Sh' Equity
|
|||
| — | 28.38% | 23.75% | 17.81% | 5.87% | (14.98%) | (2.92%) | (5.38%) | (26.75%) | (18.03%) |
ROA
|
|||
| — | 41.99% | 36.86% | 38.35% | 15.40% | (27.45%) | 1.13% | (10.22%) | (36.42%) | (31.42%) |
ROIC
|
|||
| — | 48.96% | 35.77% | 24.54% | 8.67% | (26.31%) | (5.37%) | (9.42%) | (47.63%) | (31.54%) |
ROE
|
|||
Psychemedics Corporation peers in Diagnostics & Research
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ADVB Advanced Biomed Inc. | $10.4M | 1.3× | Compare |
| BIAF bioAffinity Technologies, Inc. | $9.0M | 0.0× | Compare |
| NDRA ENDRA Life Sciences Inc. | $8.9M | 0.0× | Compare |
| XWEL XWELL, Inc. | $7.6M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TTOO T2 Biosystems, Inc. | $6.5M | 0.0× | Compare |
| PRPO Precipio, Inc. | $43.8M | 0.0× | Compare |
| MDXH MDxHealth SA | $55.5M | 0.0× | Compare |
| MBAI MBody AI Ltd. | $69.0M | 0.0× | Compare |
Psychemedics Corporation (PMD) key facts
- Psychemedics Corporation (PMD) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
- Psychemedics Corporation’s revenue for fiscal 2024 (year ended December 2024) was $19.7 million, down 10.9% from fiscal 2023.
- Psychemedics Corporation reported a net loss of $1.9 million, or a loss of $0.32 per share, for fiscal 2024.
- As of March 2, 2026, PMD traded at $2.67, a market capitalization of $15.7 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.8× sales.
- Psychemedics Corporation pays an annual dividend of $0.28 per share, a yield of 4.79%.
- Return on equity was −31.5% and debt-to-equity 0.01.
Psychemedics Corporation (PMD) Latest News
16 Jun
Psychemedics Corporation released its 2025 Workforce Insights Report, highlighting the rising threats of synthetic opioids, particularly fentanyl and nitazenes, and increased drug use in high-pressure industries like healthcare and manufacturing. The report indicates a 10% rise in workplace injuries among young workers in states with legalized recreational cannabis. Hair testing remains the preferred method for drug detection, offering a 90-day detection window. The report emphasizes the need for comprehensive drug testing strategies to ensure workplace safety and compliance. The report outlines significant trends in drug use that could impact workplace safety and employer policies, influencing Psychemedics' market position and demand for its testing solutions.
26 Sep
Psychemedics Corporation releases its first-ever Education Insights Report, revealing rising drug positivity rates and key trends in educational institutions. The report highlights significant challenges and trends in drug testing within educational settings that could impact Psychemedics' future strategies and market positioning.
29 Aug
Psychemedics Corporation launches new ketamine hair testing service. The introduction of a new ketamine hair testing service is a significant strategic move that can have a major impact on Psychemedics Corporation's future performance and competitive positioning.
12 Aug
Psychemedics Corporation's Board of Directors approves plan to terminate registration of its common stock, following a proposed reverse stock split and delisting from Nasdaq Capital Market to save costs and focus on long-term stockholder value. The decision to deregister and delist the common stock is a significant strategic move that could fundamentally alter the company's trajectory and investor sentiment.
21 Jun
Psychemedics Corporation unveils its inaugural Insights Report, revealing drug trends in the workplace through hair testing. The report highlights significant drug trends and positive rates in the workplace, indicating a potential impact on Psychemedics' future strategies and market performance.
28 Mar
Psychemedics Corporation reports 2023 financial results. Financial results may moderately influence company's performance.
21 Mar
Psychemedics Corporation recognized as a Top 10 Employee Health Testing Services Provider for 2024 by ManageHR. Recognition as a top provider may enhance Psychemedics' reputation and attract more clients, but the overall impact on its future performance is expected to be somewhat limited.
2 Jan
Psychemedics Corporation relocates headquarters from Acton, Massachusetts, to Dallas, Texas. The relocation may moderately influence the company's operations and market positioning.
27 Nov
Psychemedics Corporation appoints Daniella Mehalik as VP - Finance. The appointment of a new VP - Finance with extensive experience is expected to have a moderately noticeable influence on Psychemedics Corporation's financial activities and growth strategy.
9 Nov
Psychemedics Corporation reports $5.7 million revenue for Q3 2023, with a net loss of $2.1 million. Initiates restructuring changes and go-to-market improvements. The financial results and strategic changes are expected to moderately influence Psychemedics Corporation's future performance.
27 Oct
Psychemedics introduces Advanced 5-Panel Drug Screen replacing marijuana with fentanyl. Introduction of a revolutionary drug screen focusing on fentanyl is a significant strategic move that could reshape the company's competitive position.
18 Aug
Psychemedics Corporation granted inducement awards to new CEO Brian Hullinger. The grant of inducement awards to the new CEO may influence key areas such as financial performance and competitive positioning.
11 Aug
Psychemedics Corporation reported a decrease in revenue and net loss for the second quarter of 2023, attributed to a labor shortage impacting clients' use of hair testing. The company settled a lawsuit and announced a transition plan for the CEO position. The financial results and strategic changes are expected to moderately influence Psychemedics Corporation's future performance and market positioning.
12 Jul
Psychemedics Corporation announces CEO succession plan. Brian Hullinger to succeed Ray Kubacki as CEO on August 17, 2023. The CEO succession plan and appointment of Brian Hullinger is a significant move that could alter the company's trajectory and investor sentiment.
19 May
Investors advised to check 3 factors before buying Psychemedics Corporation for upcoming dividend. The article suggests potential influence on financial performance and investor sentiment.
13 May
Psychemedics Corporation (NASDAQ:PMD) is paying out a dividend of $0.07 per share on 8th of June. The dividend payment may have a moderately noticeable influence on the company's financial performance.
9 May
Psychemedics Corporation reports Q1 2023 financial results, declares cash dividend. Financial results and dividend declaration may moderately influence company's performance.